Home > Insider Trading > Filing (0001209191-14-074332)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1062822	Lexicon Pharmaceuticals Inc.	LXRX	Pharmaceutical Preparations (2834)	760474169

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053890	Raymond Debbane	C/O Ulys, L.l.c. 750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1340098	Ulys, L.l.c.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1378005	C.v. Invus	Marten Meesweg 25 Rotterdam P7 3068AV	Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-12-10	315,896	$0.90	30,098,505	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	34,685	Direct

Footnotes

These securities are directly held by Invus C.V.
These securities are directly held by Mr. Raymond Debbane.
Ulys, L.L.C. is the general partner of Invus C.V., and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.8946 to $0.9093, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.